Profile data is unavailable for this security.
About the company
Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.
- Revenue in AUD (TTM)204.18m
- Net income in AUD117.29m
- Incorporated2001
- Employees--
- LocationNeuren Pharmaceuticals LtdSE 201 697 Burke Rd, CamberwellMELBOURNE 3124AustraliaAUS
- Phone+61 39092-0480
- Websitehttps://www.neurenpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lushang Freda Pharmaceutical Co Ltd | 845.89m | 50.19m | 1.53bn | 3.65k | 30.43 | 1.76 | -- | 1.81 | 0.2327 | 0.2327 | 3.92 | 4.02 | 0.4694 | 0.7941 | 7.74 | 1,091,879.00 | 3.23 | 0.6992 | 5.93 | 5.12 | 48.73 | 20.23 | 6.87 | 3.45 | 2.96 | -- | 0.0896 | 40.33 | -64.65 | -12.29 | 567.44 | 13.36 | 44.40 | 14.87 |
| Polypeptide Group AG | 526.31m | -45.92m | 1.53bn | 1.28k | -- | 2.64 | 420.07 | 2.92 | -0.8038 | -0.8038 | 9.23 | 10.13 | 0.522 | 1.92 | 4.90 | 252,811.20 | -4.55 | 2.59 | -6.20 | 3.26 | 9.26 | 23.73 | -8.73 | 4.58 | 0.7224 | -0.8348 | 0.2434 | 15.79 | 14.60 | 12.36 | -762.29 | -- | 25.40 | -- |
| Procter & Gamble Health Ltd | 210.78m | 39.57m | 1.54bn | 1.34k | 39.05 | -- | 34.77 | 7.33 | 131.10 | 131.10 | 698.14 | -- | -- | -- | -- | 8,680,689.00 | -- | -- | -- | -- | 71.42 | -- | 18.77 | -- | -- | 441.58 | -- | -- | -6.37 | -- | -12.42 | -- | -- | -- |
| China Animal Husbandry Industry Co., Ltd | 1.15bn | 18.65m | 1.55bn | 4.33k | 83.07 | 1.33 | -- | 1.35 | 0.0861 | 0.0861 | 5.31 | 5.37 | 0.6127 | 4.56 | 3.76 | 1,254,216.00 | 0.7085 | 6.23 | 1.00 | 9.01 | 16.42 | 24.29 | 1.16 | 8.69 | 1.54 | -- | 0.1909 | 31.20 | -8.24 | 4.04 | -26.73 | -0.6127 | 24.20 | -3.77 |
| Zhejiang Ausun Pharmaceutical Co Ltd | 177.23m | 54.65m | 1.55bn | 1.17k | 28.35 | 3.19 | -- | 8.77 | 0.3111 | 0.3111 | 1.01 | 2.76 | 0.2788 | 1.09 | 2.84 | 711,439.10 | 8.60 | 9.38 | 11.35 | 12.84 | 54.34 | 53.09 | 30.84 | 27.14 | 2.00 | -- | 0.156 | 23.53 | 6.83 | 27.35 | 7.87 | 42.07 | 24.32 | 50.48 |
| Neuren Pharmaceuticals Ltd | 204.18m | 117.29m | 1.59bn | -- | 13.57 | 7.25 | 13.54 | 7.78 | 0.9163 | 0.9163 | 1.58 | 1.71 | 1.25 | -- | 16.04 | -- | 72.03 | 49.80 | 75.50 | 55.37 | -- | -- | 57.44 | 50.10 | -- | -- | 0.00 | 0.00 | 1,403.22 | 76.78 | 85,270.11 | 119.64 | -- | -- |
| Jinyu Bio-Technology Co Ltd | 286.47m | 34.98m | 1.64bn | 1.65k | 46.51 | 1.42 | -- | 5.73 | 0.1484 | 0.1484 | 1.21 | 4.84 | 0.197 | 2.10 | 1.62 | 816,227.80 | 2.36 | 4.82 | 2.74 | 5.68 | 54.60 | 58.78 | 11.97 | 19.91 | 3.12 | -- | 0.0079 | 36.41 | 4.55 | -3.37 | 34.63 | -17.77 | -12.92 | -25.56 |
| Industri Jamu dn Frms Sd Mncl Tbk PT | 369.48m | 110.15m | 1.65bn | 3.59k | 14.97 | 4.70 | 13.60 | 4.46 | 38.07 | 38.07 | 127.71 | 121.26 | 0.9956 | 3.28 | 6.15 | 1,111,173,000.00 | 29.68 | 26.42 | 32.05 | 30.33 | 58.42 | 55.93 | 29.81 | 28.33 | 6.29 | 37.82 | 0.0009 | 95.17 | -7.75 | 5.23 | -13.95 | 7.45 | -27.13 | 11.37 |
| Holder | Shares | % Held |
|---|---|---|
| Milford Asset Management Ltd.as of 22 Mar 2024 | 6.56m | 5.05% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 3.82m | 2.94% |
| Wilson Asset Management (International) Pty Ltd.as of 30 Jun 2024 | 2.53m | 1.94% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 2.49m | 1.91% |
| Vanguard Investments Australia Ltd.as of 30 Sep 2024 | 2.31m | 1.78% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 1.56m | 1.20% |
| Milford Australia Pty Ltd.as of 31 Aug 2024 | 927.78k | 0.71% |
| BetaShares Capital Ltd.as of 31 Oct 2024 | 884.14k | 0.68% |
| Goldman Sachs Asset Management LPas of 31 Aug 2024 | 493.94k | 0.38% |
| Netwealth Investments Ltd.as of 22 Mar 2024 | 421.31k | 0.32% |
